Human TREM2 Protein, Mouse IgG2a Fc Tag, low endotoxin

ユーザーレビュー
製品番号/仕様
価格
数量
TR2-H5256-100ug
$360.00
TR2-H5256-1mg (500ug X 2)
$2615.00
ETA of in-stock products:2 business days
総アイテム数 製品金額$ 0

製品詳細

  • Synonyms

    Triggering receptor expressed on myeloid cells 2, TREM2, TREM-2

  • Source

    Human TREM2, Mouse IgG2a Fc Tag (TR2-H5256) is expressed from human 293 cells (HEK293). It contains AA His 19 - Ser 174 (Accession # Q9NZC2-1).

    Predicted N-terminus: His 19

    Request for sequence
  • Molecular Characterization

    TREM2 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a mouse IgG2a Fc tag at the C-terminus.

    The protein has a calculated MW of 44.3 kDa. The protein migrates as 55-65 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 0.01 EU per μg by the LAL method / rFC method.

  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

お客様はこちらも閲覧

データ表示

  • SDS-PAGE

    TREM2 SDS-PAGE

    Human TREM2, Mouse IgG2a Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

  • Bioactivity-ELISA

     TREM2 ELISA

    Immobilized Human TREM2, Mouse IgG2a Fc Tag (Cat. No. TR2-H5256) at 1 μg/mL (100 μL/well) can bind Anti-TREM2 Antibody, Human IgG1 with a linear range of 0.2-5 ng/mL (QC tested).

    Protocol
  • Bioactivity-BLI

     TREM2 BLI

    Loaded Human TREM2, Mouse IgG2a Fc Tag (Cat. No. TR2-H5256) on Protein A Biosensor, can bind Human APOE3, His Tag (Cat. No. APE-H5246) with an affinity constant of 9.53 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol
  •  TREM2 BLI

    Loaded Human TREM2, Mouse IgG2a Fc Tag (Cat. No. TR2-H5256) on Protein A Biosensor, can bind Human APOE2 (R154S, R176C) Protein, His Tag (Cat. No. APE-H5256) with an affinity constant of 4.48 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol

ユーザーレビュー
コメントを投稿

バックグランド

Triggering receptor expressed on myeloid cells 2 (TREM2) is a cell surface receptor of the immunoglobulin superfamily. The TREM2 is found in various tissue macrophages, such as CNS microglia, bone osteoclasts, alveolar, peritoneal and intestinal macrophages. TREM2 is also present on cultured bone marrow-derived macrophages and monocyte-derived dendritic cells. Some research have identified a rare variant of TREM2 that is a risk factor for Alzheimer disease (AD), which is the most common form of late-onset dementia.The extracellular region of TREM2 contains a single immunoglobulin superfamily domain and binds polyanionic ligands, such as bacterial lipopolysaccharide (LPS) and phospholipids8. Upon ligand binding, TREM2 transmits intracellular signals through an adaptor, DAP12 (also known as TYRO protein tyrosine kinase-binding protein (TYROBP)), which is associated with the transmembrane region of TREM2 and which recruits the protein tyrosine kinase SYK through its cytosolic immunoreceptor tyrosine-based activation motifs (ITAMs). TREM2 is a pro-tumorigenic marker of tumor-infiltrating macrophages in mouse models and human tumors that can be targeted to curb tumor growth and improve the efficacy of checkpoint blockade therapy while remodeling the landscape of tumor-infiltrating macrophages.

最新の進展

 
医薬品開発の進捗
  • 英語名:

    Triggering receptor expressed on myeloid cells 2

  • カテゴリ:

  • 市販の医薬品数:

    0 詳細

  • 治験医薬品数:

    4 詳細

  • 最新の開発ステージ:

    Phase 2 Clinical

お問い合わせ
医薬品候補ライセンス
他の関連情報
  • 製品情報
  • 製品詳細
  • お客様はこちらも閲覧
  • データ表示
  • ユーザーレビュー
  • 背景
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8